• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » T.V. Padma

Articles by T.V. Padma

India weighs mandatory UCPMP to curb unfair marketing practices

Sep. 28, 2016
By T.V. Padma
NEW DELHI – India is considering making its voluntary Uniform Code of Pharmaceuticals Marketing Practices (UCPMP) mandatory to curb unfair marketing practices by pharma companies, including providing incentives for doctors to prescribe their products.
Read More

Import of refurbished medical equipment meets strong opposition in India

Sep. 16, 2016
By T.V. Padma

India steps up drug manufacturing rules via certification

Sep. 14, 2016
By T.V. Padma
NEW DELHI – India's drug regulator has made it mandatory for employees of drug manufacturing companies to be certified by a government body over the next 15 months.
Read More

India steps up drug manufacturing rules via certification

Sep. 14, 2016
By T.V. Padma
NEW DELHI – India's drug regulator has made it mandatory for employees of drug manufacturing companies to be certified by a government body over the next 15 months.
Read More

India's manufacturing quality issues are in the spotlight, again

Aug. 31, 2016
By T.V. Padma
NEW DELHI – Indian drug manufacturing plants were under the scanner again in August, with the U.S. FDA issuing warning letters to Pfizer Inc. and Frontida Biopharm Inc. for regulatory lapses observed during inspections in plants operating in India.
Read More

India’s manufacturing quality issues are in the spotlight, again

Aug. 31, 2016
By T.V. Padma
NEW DELHI – Indian drug manufacturing plants were under the scanner again in August, with the U.S. FDA issuing warning letters to Pfizer Inc. and Frontida Biopharm Inc. for regulatory lapses observed during inspections in plants operating in India.
Read More

Looking to even the playing field, India will include locally certified devices in tenders

Aug. 18, 2016
By T.V. Padma

India’s NPPA adds 24 essential drugs to price-capping list

Aug. 10, 2016
By T.V. Padma
NEW DELHI – India’s drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), has fixed price caps on 24 essential drugs used for the treatment of cancer, HIV, bacterial infections, anxiety and cardiac conditions, a move that is expected to cut the government’s costs by a quarter.
Read More

India’s NPPA adds 24 essential drugs to price-capping list

Aug. 10, 2016
By T.V. Padma
NEW DELHI – India’s drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), has fixed price caps on 24 essential drugs used for the treatment of cancer, HIV, bacterial infections, anxiety and cardiac conditions, a move that is expected to cut the government’s costs by a quarter.
Read More

First devices emerge from innovation push

Aug. 8, 2016
By T.V. Padma
Previous 1 2 … 9 10 11 12 13 14 15 16 17 … 27 28 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe